BioNTech, Autolus form CAR T-cell therapy collaboration to advance pipeline and expand late-stage programs

Five-year study identifies long-term effects of axi-cel CAR T treatment

Axicabtagene ciloleucel, commonly known as axi-cel, is an immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of therapy, axicabtagene ciloleucel has been a game-changer in treating large B-cell lymphoma.

August 09, 2024

Vol.50 No.32

Clinical Roundup

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

A new study details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the clinical-stage cell therapy company Vittoria Biotherapeutics’ proprietary Senza5TM platform.

July 26, 2024

Vol.50 No.30

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

July 12, 2024

Vol.50 No.28

By Matthew Bin Han Ong

Drugs & Targets

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

Patients treated with CAR T-cell medicines should be monitored life-long for secondary malignancies.

June 21, 2024

Vol.50 No.25

Clinical Roundup

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

A pioneering phase I CAR T-cell therapy trial for the treatment of glioblastoma at City of Hope, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.

June 14, 2024

Vol.50 No.24

Drugs & Targets

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

The Tartu University Hospital, North Estonia Medical Centre, and Icosagen have joined forces to develop and introduce an innovative personalized cell therapy for patients in Estonia.

May 31, 2024

Vol.50 No.22

BioNTech, Autolus form CAR T-cell therapy collaboration to advance pipeline and expand late-stage programs

YOU MAY BE INTERESTED IN

Five-year study identifies long-term effects of axi-cel CAR T treatment

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

BioNTech, Autolus form CAR T-cell therapy collaboration to advance pipeline and expand late-stage programs

YOU MAY BE INTERESTED IN

Five-year study identifies long-term effects of axi-cel CAR T treatment

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Infections are a major cause of death in patients treated with CAR T-cell therapyMeta-analysis focused on causes of death, excluding relapse, recurrence

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

Can you spare 10 minutes to complete a survey?

Login

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence